Dr Lal Path

Dr. Lal PathLabs delivered a strong Q4 FY26 with revenue of ₹703 croreCurrent reported value: ₹703 crore. No comparable prior figure is available in the source record. (+16.6Current reported value: 16.6. No comparable prior figure is available in the source record.% YoY), driven by 12.9% sample volume growthCurrent 12.9% sample volume growth. Reported change: +12.9% YoY. and improving revenue per patient (₹956Current ₹956. Reported change: +7.8% YoY., +7.8% YoY). EBITDA margin at 26.6Current reported value: 26.6. No comparable prior figure is available in the source record.% contracted ~150bps YoY due to investments in infrastructure, R&D, and new lab openings (14 labs, 1,100+ collection centers added in FY26). PAT was impacted by a one-time labor code cost (₹30 cr) and a high base from last year's liquidation gain. Management guided for early-to-mid teens revenue growthCurrent reported value: early-to-mid teens revenue growth. No comparable prior figure is available in the source record. in FY27, supported by sustained double-digit growth in Delhi NCR, recovery in Suburban business, and maturation of expanded network. EBITDA margin is expected to remain in the 27-28% rangeCurrent reported value: 27-28% range. No comparable prior figure is available in the source record. as investments continue. Key risk: potential supply chain disruption from Middle East conflict could impact reagent costs if prolonged.